10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study

References

• Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–1301. doi:10.1016/S0140-6736(07)60601-1
   PubMed Web of Science ®Google Scholar
• Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17–27. doi:10.1038/ki.2015.59
   PubMed Web of Science ®Google Scholar
• Hughes J, Ward CJ, Peral B, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995;10(2):151–160. doi:10.1038/ng0695-151
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272(5266):1339–1342. doi:10.1126/science.272.5266.1339
   PubMed Web of Science ®Google Scholar
• Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years’ experience. Clin J Am Soc Nephrol. 2011;6(10):2499–2507. doi:10.2215/CJN.03530411
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418. doi:10.1056/NEJMoa1205511
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dialysis Transplant. 2018;33(3):477–489. doi:10.1093/ndt/gfx043
   PubMed Web of Science ®Google Scholar
• Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD. Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3: 4. Kidney Int Rep. 2017;2(6):1132–1140. doi:10.1016/j.ekir.2017.07.004
   PubMed Web of Science ®Google Scholar
• Edwards ME, Chebib FT, Irazabal MV, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13(8):1153–1161. doi:10.2215/CJN.01520218
   PubMed Web of Science ®Google Scholar
• Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract. 2010;16(3):574–579. doi:10.1111/j.1365-2753.2009.01169.x
   PubMed Web of Science ®Google Scholar
• Mahler C, Jank S, Hermann K, et al. Psychometric properties of a German version of the “Satisfaction with Information about Medicines Scale” (SIMS-D). Value Health. 2009;12(8):1176–1179. doi:10.1111/j.1524-4733.2009.00575.x
   Web of Science ®Google Scholar
• Hjemås BJ, Bøvre K, Mathiesen L, Lindstrøm JC, Bjerknes K. Interventional study to improve adherence to phosphate binder treatment in dialysis patients. BMC Nephrol. 2019;20:178. doi:10.1186/s12882-019-1334-x
   Web of Science ®Google Scholar
• Klewitz F, Nöhre M, Bauer-Hohmann M, et al. Information needs of patients about immunosuppressive medication in a German kidney transplant sample: prevalence and correlates. Front Psychiatry. 2019;10:(JUN):444. doi:10.3389/fpsyt.2019.00444
   Web of Science ®Google Scholar
• Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–172. doi:10.1681/ASN.2013101138
   PubMed Web of Science ®Google Scholar
• Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation. 2004;77(5):786–789. doi:10.1097/01.TP.0000110412.20050.36
   PubMed Web of Science ®Google Scholar
• Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10:135–140. doi:10.1136/qhc.0100135
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Joly D, Doll H, Sánchez-Covisa J, O’reilly K, Wang-Silvanto J. FP051Baseline results from acquire: a study measuring quality of life, and treatment preference and satisfaction of autosomal dominant polycystic kidney disease patients in Europe. Nephrol Dialysis Transplant. 2019;34(Supplement_1). doi:10.1093/ndt/gfz106.FP051
   Google Scholar
• Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:1–10. doi:10.1186/1477-7525-7-36
   Web of Science ®Google Scholar
• Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:1–13. doi:10.1186/1477-7525-2-12
   PubMedGoogle Scholar
• Yu ASL, Shen C, Landsittel DP, et al. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019;95(5):1253–1261. doi:10.1016/j.kint.2018.12.023
   Web of Science ®Google Scholar
• Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255–2266. doi:10.1056/NEJMoa1402685
   PubMed Web of Science ®Google Scholar